Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“HER2-mutant NSCLC: A new targeted option emerges.
The FDA has granted accelerated approval to zongertinib (Hernexeos) for patients with unresectable or metastatic non-squamous NSCLC harboring HER2 (ERBB2) tyrosine kinase domain mutations.
Approval is based on the Beamion LUNG-1 trial.
Key results:
- ORR: 76%
- ≥6-month response duration: 64%
- ≥12-month response duration: 44%
Zongertinib is a HER2-selective kinase inhibitor, representing another step forward in the expanding landscape of targeted therapies for oncogene-driven lung cancer.”
Other OncoDaily articles featuring Prof. Ahmet Dirican on OncoDaily.